Warfarin and bevacizumab suppress tumor progression in pancreatic ductal adenocarcinoma by targeting EGFR-PI3K-Akt signaling: inhibition of proliferation/migration and apoptosis induction
Jingjing Chen, Jianjie Ju, Jingting Wang, Limei Yang · 2025
Read Warfarin and bevacizumab suppress tumor progression in pancreatic ductal adenocarcinoma by targeting EGFR-PI3K-Akt signaling: inhibition of proliferation/migration and apoptosis induction by Jingjing Chen, Jianjie Ju, Jingting Wang, Limei Yang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12776193.txt.
Description
Jingjing Chen, Jianjie Ju, Jingting Wang, and Limei Yang test an odd drug pair against pancreatic cancer: the anticoagulant warfarin and the antibody bevacizumab. Pancreatic ductal adenocarcinoma moves on fast, rebuilds its stroma densely, and resists chemotherapy, so survival is very poor. Bevacizumab blocks vascular growth factor to curb new blood vessels. Pancreatic cancer also lifts clotting, and warfarin has anti-tumor effects on record through a related axis.
Both drugs' pathways meet on the PI3K-Akt cascade downstream of the epidermal growth factor receptor. The study joins network pharmacology, molecular docking, and cell tests. Docking assessed warfarin's binding. Cell assays measured proliferation, wound-healing migration, and cell death by flow cytometry. The authors report the pair curbs tumor growth by hitting that pathway. It blocks cell growth and spread while setting off apoptosis.
Catalog record
| CREATOR | Jingjing Chen, Jianjie Ju, Jingting Wang, Limei Yang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |